• . Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. vol. 9, pp. 88-88, doi: 10.1186/s13578-019-0351-6

    View